A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

This is an early-phase study testing a new cancer drug called BGB-B2033, given alone or combined with other immunotherapy drugs (tislelizumab and/or bevacizumab), in people with advanced or spread cancers. The cancers being studied include liver cancer, a type of stomach cancer that produces a protein called AFP, germ cell tumors, and a specific type of lung cancer that tests positive for a protein called GPC3. **You may be eligible if...** - You have one of these advanced cancers: liver cancer (hepatocellular carcinoma), AFP-producing stomach cancer, germ cell tumors with no remaining curative options, or GPC3-positive squamous lung cancer that has been treated with a checkpoint inhibitor - Your cancer cannot be surgically removed or has spread - You are in generally good health and able to carry out daily activities (ECOG 0–1) - You have at least one tumor that can be measured on scans - Your organ function (liver, kidneys, blood counts) is within acceptable ranges **You may NOT be eligible if...** - You have previously received a drug that targets GPC3 or the immune receptor 4-1BB - You have cancer that has spread to the lining of the brain (leptomeningeal disease) or uncontrolled brain metastases - You have an active autoimmune disease or a history of one likely to flare up - You have another cancer diagnosed in the past 2 years (with limited exceptions) - You require high-dose steroids or immunosuppressants - You have significant lung, heart, or bleeding conditions Talk to your doctor to see if this trial is right for you.